## **FRAME Annual Report**
www.frame.org.uk | hello@frame.org.uk | +44 (0) 300 030 1016
**2020-2021** 1/24/22
1
## **Word from FRAME Chair of Trustees**
This past year we have passed a major milestone for FRAME, celebrating 30 years of the FRAME Laboratory in partnership with the University of Nottingham. We are incredibly proud of the FRAME Laboratory, which was the first dedicated research centre focusing entirely on human-based methods that will help replace animal research in the UK, but we are also aware that, although much has been achieved since FRAME was founded, there are still millions of animals in the UK and worldwide that are used in medical and scientific research, often without eliciting much, if any, progress to understand and cure human diseases.
In 2020, 2.88 million scientific procedures involving live animals were conducted in the UK alone. Whilst an immediate end to all animal testing is not possible without halting certain areas of medical research, we believe this number of animal experiments is unnecessary.
I am privileged to be a part of FRAME as Chair of the Trustees in advocating the 3Rs – Replacement, Reduction, and Refinement. Through these principles, we can help reduce animal suffering immediately as well as pave the way for non-animal methods to take the lead in the future.
We are working hard to push for a drastic reduction in the number of procedures involving live animals by focusing on four key pillars:
- Funding research – through the ongoing work of the FRAME Laboratory, our Summer Studentships and our brand-new Innovation Grants. We are at the forefront of creating, validating, and sharing non-animal methods.
- Sharing information – with our non-animal science-centred publication, ATLA, and our education and outreach work, we are sharing the importance of human-centred science around the world. Our Training School also continues to be a leader in training researchers on how to reduce and refine animal use in experiments where no non-animal methods are currently available.
- Creating change – we are working hard to promote non-animal methods within scientific communities around the world and influence positive changes in policy.
- Building resilience – we are passionate about our work and our vision for a better future, but we know change takes time. We are working hard to increase the resilience of FRAME and the sustainability of our funding, ensuring we will be around until we achieve our vision.
I hope you enjoy reading more about our work in these areas in this report.
Finally, I would like to say a huge thank you, to you - our supporters. We are immensely grateful to have such a warm group of advocates helping us through offering partnerships and providing donations and critical advice. We are honoured to be able to work on your behalf to create a future where non-animal methods are considered scientific best practice and animals are no longer used in medical or scientific research.
Together we can create a more humane world, benefitting animals and humans alike.
Dr Anna Cadogan, FRAME Chair of Trustees
www.frame.org.uk | hello@frame.org.uk | +44 (0) 300 030 1016
2
## **Welcome from FRAME CEO**
The past year has been challenging year for us all, but one thing the COVID-19 pandemic has highlighted is the urgent need for good – by which I mean robust, reliable, efficient, and effective – science as well as the important role of information sharing and collaboration within both academia and the scientific industry. The search for possible vaccines and treatments has created an unprecedented level of openness in the research community and has shone a light on the alternative, non-animal technologies being used to gather data about the virus.
Throughout the pandemic, FRAME’s work to research alternatives to the use of animals in medical and scientific research, education and testing has continued, and we cannot thank our supporters and corporate sponsors enough for their continued support, interest, and enthusiasm for our vision of a world where nonanimal methods are accepted as scientific best practice.
Despite the challenges of the pandemic, work in the FRAME Laboratory continued, with our scientists focusing on desk-based research when the lab temporarily closed due to lockdown. We’re proud that the FRAME Lab has worked on a number of successful, human-relevant projects this year, including developing an _in vitro_ model to study chemotherapy-associated liver disease; collaborating with the University of Helsinki to investigate gut microbiota in IBS, and working with the MRC Versus Arthritis Centre for Musculoskeletal Ageing Research on a human dietary study.
Every year, FRAME delivers an annual FELASA (Federation of European Laboratory Animal Science Associations) accredited Training School, held in collaboration with the University of Nottingham. Due to the pandemic, the event moved online but the course was delivered successfully through live lectures and group discussions that encouraged interactivity and collaboration.
The pandemic also led us to make changes to our Summer Studentship programme, developed to support undergraduates in undertaking research projects in an area relating to the development of alternative methods. We anticipated that laboratory research projects weren’t going to be possible, so redirected the funds to other forms of research and were pleased to award three studentships looking at important areas of policy, practice, and regulation of animal research.
In June 2020, we revealed the results of our global study: ‘Fact or fiction? Mapping perceptions of animal testing ’ which we commissioned to understand current public attitudes and perceptions of animal testing and research for medical, chemical, and cosmetic purposes. Amongst its findings, the study revealed that the overwhelming majority of people (93.4%) think more needs to be done to replace and reduce the use of animals in testing and research. We’d like to say a big thank you to those who took the time to complete the survey – the information and insights we gathered will help to inform our outreach strategy and focus our key messages for the public, the education sector, policymakers, and businesses.
The events of this year will hopefully allow gains from animal research to be evaluated, alongside the important contribution of non-animal methods, to assess the current state of animal testing and – crucially – influence a future without it.
Together, it is possible to improve outcomes for human health and prevent animal suffering.
Celean Camp
FRAME Chief Executive Officer
www.frame.org.uk | hello@frame.org.uk | +44 (0) 300 030 1016
3
## **Strategy and governance**
## Our vision
Our vision is a world where non-animal methods are accepted as scientific best practice.
## Our mission
Our mission is to support the timely development and implementation of scientifically valid methods which will provide reliable data and replace the need for animal experiments in medical and scientific research, education, and testing.
## Our values
To help us to achieve our vision we have a clear set of values that help guide us in the work we do and the decisions we make. Our values are:
- Brave - we inspire change, by questioning and constructively challenging the use of animals in scientific and medical research.
- Thoughtful - our approach is research-led and considered, using expert scientific sources to demonstrate that humane and human-focussed science is better science.
- Collaborative - we work with academics, industry scientists, policymakers, and regulators. We don’t dictate, berate, or preach; we stand alongside those working within the sector to create practical solutions for better human health.
- Resourceful - we act prudently and creatively, using our resources strategically to create maximum impact.
- Supportive - we are supportive of our staff and community, open to new ideas and viewpoints and loyal to our supporters and partners. We seek to inform, inspire, and nurture the next generation of researchers.
## Our strategy
FRAME works to achieve its goals via the following strategic areas of activity:
- Funding research - To ensure scientific methods for biomedical research that improve upon the use of animals continue to be developed and implemented.
- Sharing information - To ensure that information about non-animal methods, how to find, and how to use them is disseminated and shared as widely as possible within the scientific community at all levels.
- Creating change - To actively promote uptake of non-animal methods, ensure that barriers to adoption are reduced, and engage in constructive challenge around the inherent problems of animal models.
- Building resilience - To ensure that FRAME is a sustainable and resilient organisation with sufficient skills, support, and income to continue its work in the long term.
www.frame.org.uk | hello@frame.org.uk | +44 (0) 300 030 1016
4
## **Strategy and governance**
FRAME believes that the use of animals in research has always been scientifically questionable, and there is a growing evidence base supporting this view. Combined with the development of better alternatives and changing attitudes towards animals within society, we believe that animal research should now not be considered appropriate for the majority of research into human diseases and their treatments.
The current system of research, funding, regulation, discovery, and publication has evolved around the requirements for animal research and attempts to control and justify the use of animals. As a result, it can be difficult to make a change both at an individual and a system level.
We believe that lasting change needs to involve everyone – current and future scientists to embrace new methods, regulators to put more stringent requirements on animal research and enforce these, funders to encourage work that involves non-animal methods to build the evidence base, journal editors to ensure that high quality original research conducted in new ways can be shared and that where animal studies are published they are of high quality and reproducible, and the public to get involved in research and consider donating tissue or organs for scientific research.
## Theory of change
www.frame.org.uk | hello@frame.org.uk | +44 (0) 300 030 1016
5
## **Funding research**
## The FRAME Laboratory
FRAME continues to provide the FRAME Laboratory at the University of Nottingham Medical School with an annual block grant to support the laboratory, staff and students in their research work using humanrelevant, non-animal methods. The experimental work carried out in lab marries excellent basic science with practical scientific alternatives to the use of animals in medical experiments.
Practical research at the FRAME Laboratory halted temporarily during lockdown and some students took up opportunities to support COVID testing facilities in the early stages of the pandemic. Laboratory research swiftly resumed under social distancing guidelines.
Despite the challenges of the pandemic, students continued to work on their PhD projects with two completing them. A study involving the FRAME Lab looking at time restricted feeding on insulin sensitivity in men as opposed to mice models was also published in the American Journal of Nutrition. Several other papers were worked on, and manuscripts written and prepared for submission, including work on scaffolds for growing 3D cell models, and liver injury models.
## Work in the FRAME Laboratory is based around three key pillars:
- Neuroinflammation – The lab’s interest in neuroinflammation is driven by the significant influence it has on human health. Our scientists are building human-based models to allow them to figure out how and why neuroinflammation occurs with the ultimate aim of developing new treatments. The lab is conducting this research using induced pluripotent stem cells – stem cells which can be turned into cells such as neurones, astrocytes and microglia that can be combined to create a mini organ. The scientists also work on proteins with pre-identified drug targets that have shown promise at phase I and II trials for conditions such as Parkinson’s.
- The liver - The liver is an important focus of the lab’s research as there are currently no available treatments for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). In NAFLD, fat accumulates in the liver. Over time, this leads to inflammation and then fibrosis – scarring of the liver. To model this process, the lab uses all the primary human cells involved in the liver, including hepatocyte cells, Kupffer cells, stellate cells and cells with liver disease (fibrosis), all derived from liver samples which are ethically sourced from hospitals in the East Midlands region. The lab is also isolating the cells that our scientists believe are adult stem cells and is growing and differentiating these to produce hepatocytes. Scientists then produce ‘scaffolding’ from donated human liver tissue that has had the original cells removed. New cells (healthy or diseased) can be inserted by our researchers to produce mini organs that can be used to investigate liver diseases, toxicity, and the effectiveness of potential drugs.
- Biomaterials - The lab is researching ways to produce 3D and 2D materials that will provide an ideal environment for building cells. One project includes the creation of electrospun scaffolds – a synthetic biomaterial that can mimic cell architecture found in the human body. This will improve the quality and accessibility of _in vitro_ models as viable alternatives to animals across a range of research areas.
www.frame.org.uk | hello@frame.org.uk | +44 (0) 300 030 1016
6
## **Funding research**
The FRAME Summer Studentship Programme is an annual initiative that offers grants to undergraduate students to allow them to carry out a summer research project in an area relating to the development of alternative methods.
Despite the ongoing COVID-19 pandemic, we were still keen to support undergraduate research projects. Lockdown meant that many grants for practical research projects had to be postponed, as students and supervisors were unable to carry out laboratory work. To ensure we could continue to support students, we decided to redirect the funds during 2020 to allow applications for desk-based research projects and reviews only.
We were pleased to receive a number of interesting applications for our revised grant call and to award three grants. The funded projects were:
The use of animal models in respiratory diseases research – Martina Bonassera, Cardiff University
Martina’s project looked at the use of Non-Technical Summaries (NTSs) to sustain the Replacement, Reduction and Refinement of animal use in Respiratory Disease Research. Her research found that in many cases the accuracy and transparency of the NTS was poor, but that changes to the EU requirements in 2020 had improved this. As the only publicly available source of information on what individual studies are being carried out on animals, the NTS is a valuable source of information, and also allows for independent scrutiny of the application of the licensing legislation. She concluded that studies that assess the quality of NTS reporting in different fields of research could be a valuable source of information not only for the general public but also for competent authorities and the whole scientific community.
## Single species testing in pharmaceutical drug development – Caterina Dixon, University of Cambridge
Caterina’s project used bioinformatics (computer-based technology and tools for analysing and understanding biological data) to collate and analyse available biological data to identify specific physiological differences between animal species and the impact this has on their response to different drugs. Whilst her results were inconclusive, this project highlights possible avenues to create potential tools for assessing species relevance through the use of available data and suggests possible next steps.
Commenting on the experience, Caterina said: “ _To put simply, I could not have done my project without FRAME. They have supported me throughout the process, giving advice, checking that the project was on track and making me feel like I was part of a group much larger than just me and my supervisor. I feel truly honoured to have been given a chance to conduct research in such a vital branch of science. Thank you FRAME for this opportunity.”_
## Tackling Alzheimer’s disease: how well do mouse models work? – Gréta Utassy, Cardiff University
Gréta’s project reviewed mouse models used in published Alzheimer’s disease research over the past decade. Gréta identified the strain of mice used in each project and used a scoring sheet to assess the physical and behavioural characteristics of the mouse strain in comparison to the presentation of Alzheimer’s disease in people. She concluded that whilst the mice strains may be relevant to particular research questions, none of the models used could accurately replicate all aspects of the disease, particularly the molecular changes seen in the brain resulting in the formation of plaques and tangles as seen in Alzheimer’s cases. Gréta also created a scoring system to assess the potential reproducibility of each study using criteria from the ARRIVE guidelines for reporting animal research. Ensuring animal studies are reported thoroughly and accurately is important for assessing the value of the research and the outcomes.
www.frame.org.uk | hello@frame.org.uk | +44 (0) 300 030 1016
7
## **Sharing information**
Sharing information is a core element of our work at FRAME in our mission to replace the need for animal experiments in medical and scientific research, education, and testing.
This year, despite the global pandemic, we have continued to share information with key audiences who all have parts to play in helping us achieve our mission. We have also strengthened our resources to increase our capacity and enable us to do this more effectively moving forward.
Our goal was to disseminate information on non-animal research methods, how to find and use them, raise awareness of initiatives, issues and regulatory changes, and share training and funding opportunities within the scientific community at all levels.
This year we achieved this through:
- Sharing information with the public to raise awareness of our work in replacing animals in research and show donors how their gifts are being used to bring change. We shared local and global initiatives and relevant campaigns that increase voices pushing for a move to non-animal research methods, to educate and provide more insight and context to animal and non-animal research issues and how we can path the way to change.
- Sharing information with future scientists, regulators, and decision makers to raise awareness of modern non-animal technologies, the 3Rs, research ethics, good experimental deign and increase knowledge of the regulatory framework for using animals in research, how to find and use alternatives and areas for improvement within the current system.
- Launching a new website . Following the appointment of FRAME CEO Celean Camp, FRAME started to evolve a new strategy and plan to ensure we had the correct people and infrastructure in place to facilitate the sharing of information with our audiences effectively and efficiently. As part of this, a project to create a new website began in summer 2020, with the aim of making information and resources more accessible to everyone. The website launched in February 2021.
- Researching and publishing a report on attitudes to animal testing . We commissioned a global survey with the aim of increasing understanding of public awareness and attitudes to animal research and gather insights that would inform FRAME’s future messaging. The report: ‘Fact or Fiction: Mapping perceptions of animal testing’ was published on the FRAME website in June 2020.
Amongst its findings, the survey revealed that:
- **93%** of the general public think more needs to be done to replace and reduce the use of animals in testing and research
- **52%** of people think stopping the use of animals in all types of research and testing could happen immediately.
- **42%** of people see greater funding of alternatives as the most important factor in helping to end the use of animals in testing and research.
- **75%** of survey respondents see the pharmaceutical industry as the biggest user of animals for research and testing.
www.frame.org.uk | hello@frame.org.uk | +44 (0) 300 030 1016
8
## **Sharing information**
- The findings of the research were cited later in 2021 in an open letter to the ECHA (European Chemicals Agency) in response to its decision calling for animal tests on chemicals for cosmetics use, and signed by over 400 companies and organisations from the cosmetics industry. The report was also referenced in global news coverage of the campaign, including articles in The Guardian, Elle, Harper’s Bazaar, and Business Telegraph.
- Developing our partnership with the University of Nottingham. Throughout 2020 and 2021 we have continued our partnership with the University of Nottingham and explored opportunities for expanding this in the future. We work closely with colleagues in the Centre of Applied Bioethics where we support the post of Research Fellow Dr Michelle Hudson-Shore to continue her work on joint projects such as the FRAME Training School in Experimental Design and other training provisions. We also continue to fund the FRAME Laboratory annually and maintain close links with Dr Andrew Bennett, the Director and supervisor of the PhD students and their lab projects.
- Delivering a virtual Training School. FRAME has held annual Training Schools in experimental design and statistical analysis of biomedical and bioscience experiments since 2008. These training courses are now held in collaboration with the University of Nottingham. Historically, these courses have been face-toface, but the pandemic meant that the 2020 Training School due to take place at the Moredun Research Institute had to be postponed. Following overwhelming support and interest in an online event, FRAME shifted the approach to deliver the training virtually in April 2021.
- Publishing Alternatives to Laboratory Animals (ATLA). We continued to publish our peer-reviewed, scientific journal ATLA in partnership with SAGE Publishing. In May 2020, Professor Judith Madden of Liverpool John Moores University was appointed as ATLA’s new Editor-in-Chief. In January 2021, Esther Haugabrooks (Physicians Committee for Responsible Medicine, Washington DC, USA), Helena Kandarova (Slovak Academy of Sciences, Bratislava, Slovakia), Winfried Neuhaus (Austrian Institute of Technology, Vienna, Austria) and Alicia Paini (European Commission, Joint Research Centre, Ispra, Italy) all joined ATLA as Associate Editors.
There were around 30,000 full text downloads from the SAGE/ATLA platform this year. The most frequently downloaded paper from the April 2020–2021 ATLA issues was a comprehensive review of _in silico_ tools as alternatives to animal testing.
Authors of papers in the April 2020–2021 ATLA issues were from various countries, including India, the Philippines, Turkey, Egypt, the Netherlands, and the Czech Republic, amongst others. Papers featured a wide range of subjects, such as the environmental toxicity testing of hospital wastewater using _in vitro_ methods; intestinal organoids; an evaluation of blood–brain barrier models; a lung inflammation model; and a critique of the use of animal models in psychiatric disorders.
Four Virtual Special Collections were launched in March 2021. These covered education and training resources; _in silico_ tools; serum-free approaches; and biobanking. The aim is to create a platform of collated papers on these specific topics on the ATLA website. This will represent a valuable resource of information for a wide and varied audience, including research scientists, educators, policy makers and regulators.
www.frame.org.uk | hello@frame.org.uk | +44 (0) 300 030 1016
9
## **Creating change**
FRAME promotes the use of non-animal methods through activities such as campaigning, funding and the publication of research, and through our educational work and resources. We promote robust scientific methods and available non-animal techniques and their benefits, to the current scientific community and scientists of the future.
Through our own research, FRAME is continually investigating and developing new methods at the forefront of science. We also collaborate with other organisations, industry, and laboratories across a wide range of biological and medical fields to help advance science and bring change.
Our goal was to promote uptake of non-animal methods, ensure that barriers to adoption are reduced, and engage in constructive challenge around the inherent problems of animal models.
This year we achieved this through:
- Supporting Home Office working groups. FRAME has a history of advising the UK government in the development of policy around the use of animals in science and the implementation of alternative methods. To this end, we remain a member of the Animal Welfare stakeholder group and attend meetings held by the ASRU (Animals in Science Regulation Unit) - the Home Office unit responsible for regulating the operation of the Animals (Scientific Procedures) Act 1986 (ASPA). As a result of this association, at the start of 2021, FRAME was asked to contribute to the ‘Future Capability Working Group’ set up by the Animals in Science Committee (ASC). The Animals in Science Committee (ASC) is a non-executive, non-departmental public body established under the requirements of ASPA to provide independent expert advice to ministers on matters relating to the welfare of species protected under the Act and their use in scientific procedures. FRAME completed and submitted two horizon scanning documents on key issues we felt would potentially impact the use of animals in research in the future. One summarised key concerns around GA (genetically altered) animal use in research, and the other the need to prioritise non-animal methods more robustly. We also took part in the follow-up workshops in 2021 alongside other invited attendees.
- Facilitating volunteering opportunities. Volunteers are key to the work of many charities, contributing to fundraising, events, and administrative tasks. Due to the nature of FRAME’s mission, it is essential that we stay abreast of changes in regulation, policy, training, funding and advances in research in order to share and signpost relevant content and news to the right audiences, as well as informing our own work. Following on from volunteering enquiries from people with the skills to help support these aspects of our work, FRAME took on a volunteer to support ongoing projects at the end of 2020 and an PhD intern at the beginning of 2021. The opportunity to engage with scientists and future policymakers early in their career and support the development of their knowledge and skillset is something we are passionate about. In the next few years, we aim to build our volunteer network and capacity to offer similar opportunities.
Jessie Hellier joined FRAME in November 2020 as a volunteer which successfully led to the full-time role of policy and projects intern. As a volunteer, Jessie supported our work around the 30[th] anniversary of the FRAME Lab and helped us to reconnect with our alumni around the world.
www.frame.org.uk | hello@frame.org.uk | +44 (0) 300 030 1016
10
- In February 2021, FRAME welcomed Margarita Kalamara, Molecular Microbiology PhD student at the University of Dundee, as an intern as part of the Professional Internship for PhD Students (PIPS) scheme, funded by the Biotechnology and Biological Sciences Research Council’s (BBSRC) through the East of England Bioscience (EASTBIO) Doctoral Training Partnership. The scheme provides students with the opportunity to carry out a work placement unrelated to their doctoral research during their PhD, to help early career researchers understand the context of their research and allow them to explore the range of opportunities in which they can apply their PhD skills and training after they graduate.
At FRAME, Margarita carried out a project reviewing the provision of experimental design and 3Rs training on PhD courses at universities across the UK, with the aim of identifying where improvements can be made and how FRAME can influence change.
Margarita's final report highlights large variety in mandatory and optional training provision between universities and institutions.
Commenting on the opportunity, Margarita said: _“Being able to work as part of a charity that does such important work has been fantastic. Not only have I learnt about the field of researching and promoting alternatives to animal methods, but I have also experienced what it is like to work in the third sector. Having the chance to explore alternative careers to academia and learn about my areas of interest in the context of a Professional Internship is a great privilege and I am very grateful to EASTBIO and everyone at FRAME for all their support.”_
- Sustaining supporter and external communications. We continued to disseminate key news, views and updates via the new FRAME website and social media platforms including Facebook, Twitter, Instagram, and LinkedIn. Articles covered key areas of concern and interest for FRAME such as the use of GA animals, accelerating the uptake of alternatives, the impact of the COVID-19 pandemic on animal research and ongoing research projects in the FRAME Laboratory including diabetes and breast cancer. We also increased our email communication to subscribers, with e-shot updates issued twice a month.
In 2020, FRAME was approached by HelpFilm – a charity that provides free professional animations for non-profit organisations. Together, we produced an animation summarising our key mission to replace animal research and how we are trying to get there. The animation is available to view on ‘The Issue' page of our website.
In total, 35 news articles and blogs were uploaded to the FRAME website, and two issues of our print newsletter, FRAME News, were sent out to subscribers.
In October 2020, FRAME’s thought leadership article, ‘Human models for human drug development’ was published in Drug Discovery World – one of the leading sources of drug discovery and development news. The article questions why the outdated practice of using animals has not yet been sufficiently challenged, discusses the need for a shift in ‘replacement’ thinking, and explores what needs to be done to make responsible, reproducible, human-relevant approaches a first choice for research teams across industry and academia, as well as the part industry insiders can play.
- Recruiting new expertise to FRAME’s Board of Trustees. In June 2020, we appointed Dr Carol Treasure, founder and CEO of specialist animal-free contract testing laboratory, XCellR8, to our Board of Trustees. The appointment of Dr Lesley Gilmour, the Named Training and Competency Officer (NTCO) at the University of Glasgow, closely followed. The Board provides strategic direction and governance and works alongside the FRAME team that is led by CEO Celean Camp.
www.frame.org.uk | hello@frame.org.uk | +44 (0) 300 030 1016
11
## **Building resilience**
**----- Start of picture text -----**
Change in investment values - £182,982
£24,645
£51,675
£0
£24,857 £209,700
Total income:
£35,417 Total expenditure:
£480,110
£310,256
£343,516
£217,420
£66,118
**----- End of picture text -----**
We know that the effects of the COVID-19 pandemic have been far-reaching and have caused financial challenges and hardship for many. We’re extremely grateful to those who have continued to support us this year, and in particular our generous legacy donors who have helped sustain us for more than 50 years.
We rely entirely on donations and gifts to carry out our work, and appreciate each and every donation we receive.
This year, we have made a number of key investments to ensure that FRAME is a sustainable and resilient organisation with sufficient skills, support and income to continue its work in the long term.
These include:
- Appointing FRAME’s first Fundraising Manager – Catriona Sinclair joined FRAME as Fundraising Manager in January 2021 to build on our engagement and outreach work and strengthen relationships with stakeholders. Catriona is responsible for generating income for charitable activities and keeping in regular contact with the charity’s donors and supporters, as well as connecting individuals, businesses, and other organisations with FRAME’s work.
- Launching a new website – In 2020, the appointment of Celean Camp as CEO, along with the onset of the pandemic, provided the ideal opportunity for us to review FRAME’s marketing strategy and identify new opportunities and ways to engage with our target audiences. It was quickly identified that our existing website didn’t provide the necessary functionality to allow FRAME to grow and adapt to new pressures and challenges. Working with marketing and PR agency V Formation and digital agency Frogspark, we developed a new website with the aim of effectively engaging, educating, and facilitating the conversation around animal testing and alternatives. Since the website’s launch in February 2021, we’ve seen an increase in traffic and engagement, with the number of website visitors increasing and users spending more time on the site.
www.frame.org.uk | hello@frame.org.uk | +44 (0) 300 030 1016
12
## **Looking to the future**
As we look ambitiously to the future, we are focused on increasing the sustainability of FRAME by diversifying our income streams, to reduce our reliance on legacies.
We will continue to strengthen our leading partnership with the University of Nottingham, including sustaining our annual grant to the FRAME Laboratory to support staff and students in their research work using human-relevant, non-animal methods. By doing this, we are able to increase the global reach and impact of our work, creating real, tangible change by reducing the number of animals used in medical and scientific research.
In addition to funding laboratory work, we will be expanding our current education and outreach efforts through the provision of educational resources for secondary schools. We also aim to conduct key research projects to uncover the underlying issues that are blocking the adoption of non-animal methods within scientific and medical research, including a survey of researchers working in academia and industry.
www.frame.org.uk | hello@frame.org.uk | +44 (0) 300 030 1016
13
## **Thank you**
We would like to say a huge thank you to all our collaborators, donors, partners, and supporters. Without you we could not have achieved what we have this year, and we would not be able to continue working towards our goal to replace animals in scientific and medical research and testing.
FRAME is extremely grateful to the following people and organisations for their support:
- University of Nottingham
www.frame.org.uk | hello@frame.org.uk | +44 (0) 300 030 1016
14
## **FRAME Annual Report 2020-21**
Fund for the Replacement of Animals in Medical Experiments www.frame.org.uk Registered charity number: 1176266
**Call**
**Email**
## **Write to Us**
+44 (0) 300 030 1016
FRAME, Cawley House, 149-155 Canal Street, Nottingham, NG1 7HR UK
hello@frame.org.uk
www.frame.org.uk | hello@frame.org.uk | +44 (0) 300 030 1016
15
REGISTERED COMPANY NUMBER: 1176266 (England and Wales)
REGisfERED CHARITY NUMBER: 1176266
Report of th• Trustees and
Unaudlted Flnanclal Statements
for the Year Ended 31 Marth 2021
THE FUND FOR THE REPLACEMENT
OF ANIMALS IN MEDICAL
EXPEIUME14TS (FRAME) CIO
aayton & Brewill
Chartered Accountants
Cawley House
149-155 Canal Street
Nottin9ham
Nottinghamshl
NGI 7HR
THE FUND FOR THE REPLACEMENT
OF ANIMALS IN MEDICAL
EXPERIMENTS (FRAME) CIO
Cont•nts of th• Flnandal Ststements
for the year end¢d 31 March 2021
P•qe
R•port of th• Truste
Znd•p•nd•nt Examln•r'• Report
Statement of Plnandal Actlvltl•s
8•lance Sh••t
C•8h Flow Stat•ment
Not•• to the Ca*h Flow Ststement
Not•J to th• Flnandal 5tatem•nts
9 to 18
Deta11 Stat•ment of Flnanclal Actlvltl
19 to 20
THE FUND FOR THE REPLACEMENT
QF ANIMALS IN MEDICAL
EXPERZMENT5 (FRAME) CIO
Report of the Trustees
for the year ended 31 Mar¢h 2021
The trustees who are also dlrectors of the tharity for the purposes of the Companles Act 2006, present
their report with the financial statements of the charity for the year ended 31 March 2021. The trustees
have adopted the provisions of Atcountlng and Reportlng by Charities: Statement of Recommended
Practice applicable to charities preparing thelr accounts in attordance with the Financlal Reportlng
Standard applicable in the UK and Republlc of Ireland IFRS 1021 (effective l January 2019).
08JECTIVES AND AcfivTrIes
Objectlves and alm•
The charltable objecknves of FKIME, as stèted in the 1969 Trust Deed. are:
To promote the menral and moral Improvement of manklnd by worknng to relieve the sufferlng to anlmals
when being used to assess adverse human reathons In medlcal, blolo9lcal. pharmaceutical ond other
assoclated researches.
To promote or asslst in the prov151on ol research Into acceptable new technlques and substitut8s for the
use of anlmals In such medlcal, biological, phorynaceutical ond other assodated researches and promote
the publicatSon Jnd dlssemlnatlon of the results such search conducted by and in aSslatIOn with thè
Charlty and to hlghllght and comment on such researth condurted by others.
The charlty's fundamental alm Is to promote the embeddln9 of the 3Rs (Rauctlon, Reflnement and
Replacement) in blomedlcal research and development. FRAME achleves Sts objectives through
laboratory-based and olTice-based research Into non-anlmal rearch methods that enable safety testlng
of chemlcals present in cosmetlcs, foodstufts, household products and pham)aceuticals. FRAME also is
Involved In the valldation and gUlatOry acceptance of these methods, that can also be used to study
and understand human diseases and thelr treatment.
The research. based largely In the FRAME ternItjveS Lat)oratory {FAL) based In the Unlverslty of
Nottlngham Medlcal School generates publScations In peer-revlewed scienUftc Journals and presentatlons
at sclentyflc meetings. The Charlty publlshes Its own peer-vIeVd sdentlfic Joumal AT (Alternatlves
to Laboratory Animals).
FRAME'S websltes, press releases and sodal media 4re the porta15 through whlch FRAME dlssemlnates It
ctivitles and provldes èdvl¢e, consultancy and news servlces to industry, govemment, academia, and
others interested In the fidd of athrnatives to Jnlmal testing.
FRAME'S tralnlng schools offer trèinlng to research scientisvs expert •dvlce on experfmentsl design and
5tatlstlcal analysls to those undertakln9 animal procedures, In order to mlnlmlse the numbers of anlmals
used and to maximlse the value of thelr studles.
Slgnlflcant actlvltl
Enclosed within published rep)rt.
STRATEGIC REPORT
STRu¢fuRE, GOVERNANCE A14D MANAGEME14T
Governing document
The charfty Is controlled by its 9ovemlng document, a deed of trust, and constitutes a Ilmlted., corDpanyi
limited by guarantee, as defined by the Companies Art 2006.
Recrultment and appolntment of new trustees
The management of the CIO is the responslbillty of The Trustees who are elected under the tem)s of the
trust deed. Trustees are elerted on the recommendation of fellow tnjstees and there must be at least
four trustees at any one tlme, but no more than six.
OryanlsatSon)I structur•
The CIO is governed by Its knust deed. The Trustee5 exerdse ultimate control over The Fund for the
Replacement of Animals In in Medical Experiments. work and activitles ensuring Its financlal and le9al
responsibllities are property fulfilled. All Trustees give their Ume voluntarfty and Ceive no direci financial
or other benefits from the CIO.
Page I
THE FUND FOR THE REPLAceMENY
OF ANIMALS IN MEDICAL
EXPERXMENTS {FRAME) CIO
Report of the Tvustees
for the Year•Thd 31 March 2021
STRUCTURE, GOVERNANCE AND MANAGEMENT
Indurtion Jnd tralning of new trust¢e$
The inductlon and training of trustees Is viewed as an ongolng process and levant tralning opportunltles
are brought to the attentlon of the board as requlred. Newly recruited trustees are offered an induction
and training designe(l around thelr existing knowledge of The Fund for the Replacement of Animals in
Medlcal Experfments and thelr role.
Rl¥k management
The trustees have a duty to Identfy and ree the rlsks to whith the chartty Is exposed and to ensure
ppropdate controls are In place lo provide reasonable assurance a9alnst fraud and error.
REFEREPICE AND ADMINISTRATIVE DETAILS
R¢g1St¢r Compjny numhr
1176266 IEngland and Woles)
R•9l¥tered Charlty number
1176266
R•gl*t•rod offl¢•
Cawley House
149-155 Canal Street
Nottlngham
Nottlnghamshlre
NGI 7HR
Trustee•
Professor D A Kendall (reslgned 30.9.2021)
A Cadogan
G Thomson Ireslgned 30.6.2021)
M Newman {reslgned 30,6.2021)
Dr C Treasure Chalr {appolnted 22.7.2020)
Dr A Petrle {appolnted 27.1.2021}
Dr L Gllmour (appolnted 22.7.2020)
Ind¢p•nd•nt Ex•mln•r
N F South
FCA
Clayton & Brewlll
Chartered Accountants
Cawley House
149-155 Canal Street
Nottlngham
Nottlnghamshlre
NGI 7HR
Soll¢ltorn
Actons Sollcilors
20 Regents Street
Nottlngham
NGI 5BQ
Bankers
B?rclays Bank pk
Nottingham Hlgh Street Branch
PO Box 18
Nottlngham
NGI 6FF
Page 2
OF AN114ALS 114 MEDICAL
EXPEIUMEMTS (FRAME) CIO
forth• y••r •nd•d 31 M•rth 2021
Tha thirtty ao *wor*ed m th• 13th Oectsnbtr 2017 and was d¢xm•rt fty the to 30th June
20,
On 30 2019. the trjnts d all iknds WKI aSXKlatd heid by untrp(X0el dwrki, Tl
*e¢s (rf Fund fr* the RepteM* (l Anlm•L8 Sn Mtsytil Expertrnerts (Chartty numbtr.. 259464) to
the IrL¢Yrpyatrd tharfty, The FUNJ fw the RepCernei of knlma15 In Mollcal Werfmtsits ao (tharlty
Number. 1176266) Js port cltr* fiThwl wmm•it i*vfftn the tvrtl p•rtle&
thLs 41 tt4rltai4e artfve5 th• crmirnI partles
J strnr•* by order af the b)ard ¢1 trt,
•rxt 51gn&l on the boord¥ behalf by:
the dlr•Ity5, on
og•n- TriA
Independent Examlner's Report to the Trustees of
THE FUND FOR THE REPLACEMENT
OF ANIMAIS IN MEDICAL
EXPERIMENTS (FRAME) CIO
Independent examlner'$ report to the trust••s of THE FUND FOR THE REPLACEMEMf OF
ANIMALS IN MEDICAL EXPERIMENTS {FRAMe) cro ('the Company,)
I report to the charity trustees on my examlnatlon of the accounts of the Company for the year ended
31 March 2021.
Responslblllties and basis of report
As the tharity's trustees of the Company (and also its directors ft)r the purposes of company law) you are
responsible for the preparation of the accounts in accordance wlth the qu1MentS of the Companies Art
20061'the 2006 Art,).
Having satisfied myself that the accounts of the Company are not requlred to be audited under Part 16 of
the 2006 Art and are eliglble for Independent examination, I pOrt in respect of my examlnatlon of yovr
charlty's accounts as carded out under section 145 of the Charities Art 2011 I'the 2011 Act,). In carying
out my examlnatlon I have followed the Directions given by the Charlty Cornmisslon under sertlon 145(5)
Ibl of the 2011 Att.
Independent oxamln•r's *tst•fflent
Slnce your charity's gross Income exceeded £250,000 your examlner must be a member gf a Ilsted body.
I can ¢onflrm that l am qualifled to undertake the examlnatlon because l am a reg1sted member of FCA
whlch Is one of the Ilstsd bodles.
I have completed my examlnatlon. I conflrm that no matters have come to my attentlon In ,coynectlon
wlth the exjmlnauon glvlng MÈ cause to belleve:
accountSng records were not kept In respect of the Company as requlred by 5ertlon 386 of the
2006 Art: or
the a¢counts do not accord wlth those records; or
the accounts do not comply wlth the accountyng requlrements of settion 396 of the 2006 Act other
than any requlrement that the accounts give a true and falr vlew which Is not a matter consldered
as pèrt of an independent examination: or
the accounts have not been prepbred in acwdance wlth the methods and prfnclples of the
Statement of Recommended Practke lor accountin9 and reporting by charities (applicable to
tharlti'es preparlng thelr accounts In attordance with the Thnanclal Reporting Standard applicable In
the UK and Republlc of Ireland IFRS 102)).
I have no concems and have come across no other rnatters In connecdon with the examlnatlon to which
attentlon should be drawn In this report In order to enable a proper understJnding of the accounts to be
ached.
N F South
FCA
Clayton & Brewlll
Chartered Accountants
Cawley House
149-155 Canal Street
Nottingham
Noitlnghamshlre
NGI 7HR
Page 4
THE FVt4D FOR THE REPLACEMENT
OF ANIMALS IN MEDICAL
ExPEmENTs (FRAME) CIO
statement of Financlal Attlvlile5
for tha year ended 31 March 2021
2021
Total
funds
2020
Total
funds
Unrestricted
funds
Restricted
funds
Endowment
funds
Notes
INCOME AND
ENDOWMENTS FROM
Donatlons and legacles
378.933
378.933
613,371
Other trading artlvltles
Investment income
25.694
50,626
76,320
24.857
27,614
33,152
24,857
Total
404,627
50,626
24.857
480,110
674,137
EXPENDITURE 014
Rallng funds
66.118
66.118
65,705
Charltable actlvlti
Untestrtct
Grant
ternatlve Research
Publlcatlons
Managemenl & Admln
19,287
5,000
202,700
19,287
5,000
202,700
16,582
200,000
28,788
213,783
157,099
3S,268
7,766
200,133
Total
450.204
35.268
7.766
493,238
524,858
Nel galnsl(losses) on
investments
182,982
182,982
{130,291)
NEr
INCOME/(EXPENDITURE)
145.577)
15.358
200,073
169,854
18,988
Trnnsfer• between fund•
17
1,358
(1,358)
Nrt mov•m•nt In funds
(44.219)
14.000
200.073
169,854
18,988
RECONCILIATION OF
FUNDS
Tot41 lunds brought
forward
575,559
78.966
848,272
1.502,797
1,483,809
TOTAL FUNDS CARIUED
FORWARD
531,340
92.966
1,048.345
1,672,651
1,502,797
The notes form part of these f(nanaal Statements
Page 5
EXPEIUMEKfs (FRAME) ao
31 M•rth 2021
)a
2020
Totsl
fvnts
fLffjds
14
32,813
92,966 ¥048,345
1,174.124
945,271
DEbtrMs
Cbsh Jt l)ank and kn h•nd
15
74,462
603.438
74,462
603M38
24,394
4569,652
6T1,9
677,9
694,046
Awnts due
16
(179,373)
(179,373) (136.520)
498,$27
498,527
557,S26
531.340
92,966 1,048,315
1,671651
1,502,797
NEf AS$E
531,340
92,966 1,048.345
1,6n,651
1.502,797
AINCffj
17
531,340
92.966
Z,0¢8,345
575,559
78,966
848,272
thywmtrt fvnds
YOTAL FU14C4
1,672,651
1,502,797
The chJrltsblB Iwipary 15 ffjtIUed to ¢¥¢mp• fyom ll111 477 rf tre ClwIeS kt 21
tho ywr 31 Mtrth 2021.
Th¢ meml>trs hthp rKt rtquk¢d oxnpany to 1)i*•ln an a1 rf Ils finandal 5t•tements tr the y¢ar
•nded 31 March 2021 In acc¢Ydano Tnlth 476 c¢the Crynp•nles *£t 2LX)6.
The trustees Kknowlèjge thelr rEsp*11 ft
(a) Ctl¥ that chamtrblt c(¥npwry keeps that c(xnpty Settt*6 386 and
387 dthe Companies Art 2006 arKI
(b) prewlNJ findal stottyT glve a true fJlr the stjte Jffalr5 rf the
charltèble as at the erKI cl wch ftmntsal year ar•J of ts Surplus for eJch
flnandal ar In aoJxd•nce wlth u$r$ rf Secttsts 394 Ind 395 whlth r*,Ivy
tnpty wlth the reoulremerts Ctynpanfes Act 2(K6 relatlrYJ to flndal statwnents, 9) far as
awknble trj the rhrltslJl• LThlPJry.
and were on tts ty:
THE FUND FOR THE REPLACEMENT
OF ANIMALS IN MEDICAL
EXPERIMENTS IFRAME) CIO
Cash Flow Statement
for the year ended 31 March 2021
2021
2020
Notes
Cash floTJVS from operating actlvltl•s
Cash generated from operations
(37.434)
168,957
Net cash {used In)Iprovlded by opernting artovlties
(37,434)
168,957
Cash flows from Invertlng artlvltl
Pvrchase of fixed asset investments
Sale of flxed asset Investmenrs
(1,013,275)
967,404
{493,9S5)
484,872
Net cash used In Investlng artlvltles
(45,871)
19,0831
Cash Ilow• from flnanclng •thltl
Income attributable to endowment
Expendlture attrlbutable to endowment
24.857
(7,7661
44,151
110,4951
Net cash provlded by ftnanclrig actlvities
17.091
33,656
Change In S
1.502,797
169.854
1.672,651
Page 14
continued...
THE AIND FOR THE REPLACEMENT
OF ANIMALS IN MEDICAL
EXPERIMEi*fs (FRAME) CIO
Notes to the Financlal Ststements - continued
for tha year ended 31 March 2021
17. MOVEMENT IN FVNOS - eontinyed
Net movement in funds. induded In the above are as folh)ws'.
Incoming
resources
Resources
expended
Gains and
losses
Movement
n fijnds
Unr••trlthd fund•
General fvnd
404.627
{450,204}
(45,5771
Restrlrted funds
Alternatlve Researth Fund
ATLA Fund
(Ll.475)
123.793)
{11,474)
26,832
50,625
50,626
Endowment fund•
FRAME Endowfflent Fund
{35,268)
15.358
24,857
17.766)
182,982
200.073
TOTAL FUNDS
480,110
(493,238)
182,982
169,854
Comp•r•tlv•s lor mov•ment In lunds
Net
movement
in fvnds
At
31.3.20
At 1.4,19
Vnrestrlct•d fund•
General fund
Tralnlng School Fund
414,545
29,221
129.444
2,349
543,989
31,570
443,766
131.793
R•strlrted fund•
Alternatlve Research Fund
ATLA Fund
Dogs Prolett Fund
Education Fund
PILAS Fund
575.559
815
18,764
20,299
1,145
43,114
12,708
(15.839)
13,523
2,925
20,299
18051
43,024
11,9501
(901
84,137
(5,171)
7&966
Endowmant fund¥
FRAME 8111 Annett Annual Lecture
Fund
FRAME Endowment Fund
50,000
905,906
50,000
798,272
(107,6341
955.906
(107,6341
848,272
TOTAL FUNDS
1,483,809
18,988
1,502,797
Page 15
continued...
THE FUND FOR THE REPLACEMENT
OF ANIMALS IN NEDICAL
EXPERIMENTS IFRAME) CZO
Notes to the Flnancial Statements- continued
for the year ended 31 March 2021
17. MOVEMENT III FUNDS- continued
Comparative net movement in lunds, Induded In the above are as follows..
Incomln9
Resources
expended
Garn5 and
losses
Movement
in funds
Unr¢*trfcted funds
Genernl fund
Trainlng School Fund
612.392
2.936
{482,948)
(587)
129,444
2,349
615,328
(483,535)
131,793
Rostrlrted funds
Alternatlve Research Fund
ATLA Fund
Edueatlon Fund
PIW Fund
12.708
12.949
12,708
(15,839}
(1,9501
(901
(28,7881
(1.950)
190)
25,657
(30.8281
Endowment funds
FKAME Endowment Fund
(5,171)
33.152
(10.495) (130,291) (107,634)
TOTAL FUNDS
674,137
(524,8581 (130,291)
18,988
A current year 12 months and prtor year 12 months comblned posltlon Is as follows:
Net
movement
in funds
Transfers
between
funds
At
31.3.21
At 1.4.19
Unrestrfrted fund•
General fund
Trainlng School Fund
414,545
29,221
83,867
2,349
1,358
499,770
31,570
443,766
86,216
R•8trlrted luftd•
Alternatt Research Fund
ATLA Fund
Dogs Projert Fund
Educatlon Fund
PILAS Fund
1,358
531,340
815
18,764
20.299
1,14S
43,114
1,234
10,993
11,474
112,8321
13.523
16,925
20,299
IB051
43,024
{1,950)
(90)
84,137
10.187
Endowment
FRAME Bill Annett Annual Lerture
Fund
FRAME Endowment Fund
{1,358)
92,966
50,000
905.906
50,000
998,345
92,439
955,906
92,439
1,048,345
TOTAL FUNDS
1.483.809
188,842
1,672,651
Page 16
contlnued...
THE FUt40 FOR THE REPLACEMEKr
OF ANIMALS IN MEDICAL
EXPERIMENTS (FRAME) ao
Notes to the Finanaal Statements - continued
for the year ended 31 March 2021
17. MOVEMENT IN FUNDS- continued
A current year 12 months and prfor year 12 months comblned net movement In funds, Induded In
the above are as follows:
Incoming
Resources
expended
Galn5 and
losses
Movement
In funds
Unrestrlrted fund•
General fund
Tralnln9 School Fund
1,017,019
2,936
(933,152)
{5871
83,867
2,349
1,019.955
{933,739)
86,216
R¢strlrted funds
Alternatlve Research Fund
ATLA Fund
EducatSon Fund
PILAS Fund
12.709
63.574
(11.475)
<52,581}
{1,950}
(901
1,234
10,993
(1,9501
1901
76,283
{66,0961
10,187
Endowment fund•
FRAME Endowment Fund
58.009
(18,261)
52.691
TOTAL FUNDS
1,154,247 (1,018.096)
52,691
196,842
Unrestricted Fund¥
The General fund covers the ordlnary day-to-day expendlture of the ¢h•rlty.
The General fund Is able to benefft from the transfer of investment Income earned by the
Endowrnent fund for any year, so as long as the transfer of such Income does not rèsult In the
Unrestrtcted fund either maklng a surplu5, or a larger surplus, in the year In whkh the transfer Is
mède.
The Tralning School lund Is a Designated fvnd for the tharltable purpose of runnlng tralning
courses In furtherance of FRAME'5 charttable acyvltles. Any 5urplu5es generated are relnvested in
future courses.
Re*tTlrted Pund•
The Alternatlves Research fvnd is made up of donations given for the purpose of supporbng. . the
sclentlflc research work carrled out or commlssioned by FRAME.
The ATLA fund Is made up of donations given for the purpose of suppordng the publlcatlon of
FRAME'S sclentlflc loumal Alternadves to Laborntory Anlmals.
The Do9s Project ftind is made up of donations glven for the purpose of research into the use of
dogs in medical expedments.
The HLAS fvnd exlsts to promote actlve dlscusslon of dlfferent perspethves In the use of
laboratory animals in medical experiments.
Endowment Funds
During the year ended 31 Mèrch 1989 the charlty established the FRAME Endowment Trust. The
objectlve of this lund was to enable the charity to finance long temi research expendlture by
investment income from the Endowment fvnd. rather than relylng largely on current year Income,
Part of the fijnd's capltal has prevIouY been used to purchase Russel & Burch House in oréer to
reduce the chadty's regular expendlture.
Since Its creatlon, the Endowment fund has benefitted, periodically. from the transfer of surplus
unrestrfrted operations fund incorne. Such transfers have been made solely at the trustees,
dlscretlon who have tained the right to release these funds bad( to the General fvnd if required.
Page 17
continued...
THE FUND FOR THE REPLACEMENT
OF ANIMALS IN MEDICAL
EXPERIMEpifs (FRAME) CIO
Not•s to th• financlal Statements - continued
for the year ended 31 14arch 2021
17. MOVEMENT IN FUNDS- continue
The charlty has applled for and been granted perniissTron by the Charity Commlsslon to utilise the
Endowment fund to assist with the cash flow of the drity when requlred.
The FRAME &ll Anrhett Annual lettu Endowment Fund constitutes a non-expendable financ5al
reserve, the Interest on which Is use(1 to contribute towards the charfty'5 Cost of holdlng the 5111
Annett Lerture (formerly the FRAME Annual Lecbjrel held for the flr5t tlme In September 1999,
18. CAprrAL COMMITMENTS
2021
2020
Contrarted but not provlded for In the flnanclèl statements
19. RELATED PARTY DISCLOSURES
Durlng the year, the trustees declared that they had no potential confllcts of Inte5t.
Page 18
ThE FUND FOR THE REPLACEMENT
OF ANIMALS IN MEDICAL
EXPERIMENTS (FRAME) CIO
D•talled Statemerrt of financlal Artlvltl¢s
for the year ended 31 March 2021
2021
2020
114COME AND ENDOWMENTS
Donatlons and 1•9a¢i•*
Donations
Glft ald
Legacles
33,688
1.729
343.516
56,471
1,554
555,346
378,933
613,371
Other tradlng actlvltles
Fundralsing
Publlcatlons
24.645
51,675
26,947
667
76.320
27,614
Investment Income
Investment Income
24,857
33,152
Total Incomlng Msoure
480, 110
674,137
EXPENDITURE
Ral•lng donatSon• and l•gacl
Travel and subslstencè
Advertlslng
Subscriptlons
Prfntin9
Staff tralnlng and development
Sundry
65
62,441
2,154
901
557
405
57,210
2,973
I,S47
3,006
564
66,118
65,705
Ch•rftable actlvftlgl
Trustees, expenses
Wages
Soclal securfty
Penslons
Prir)Ung
Postage
947
55,471
21,574
15,853
30,317
631
352
68
2,153
3,900
2,673
1,640
11,L38
18,526
419
980
463
3,002
532
170,639
100,957
22,630
L8.455
1,875
412
81
695
495
StatSonery
Sundrles
Travel and subslstence
Subscrlptions
Icr malntenance
Training School consultancy
Legal and professronal fees
esearch and dlssemlnatlon
Telephone
Rates
Insurance
Repairs
Carried forward
538
2,923
15,300
8,195
1,251
649
2,805
31
177,292
Thls page does not forni part of the statutory financial statements
Page 19
THE FUND FOR THE REPLACEMENT
OF ANIMALS IN MEDICAL
EXPemENTs (FRAME) CIO
Detalled Statement of Flnantial Artivities
for the year ended 31 March 2021
2021
2020
Charitable artlvltl
Brought forward
Forelgn exchange gain/loss
VAT
Accountsnry fees
Independent examlnatlon fees
Bad debt wrfte off
ATU fees
Computer equlpment
Grants to instStulion5
177,292
170,639
{1.593)
20,243
27,118
6,760
20,000
12,077
230
203,679
21,128
14,700
4,300
209.700
427,120
459,IS3
Totsl resources expended
493,238
524.858
N•t (expendltur¢)/ln¢ome befor•
g•ln$ and losses
(13.128)
149,279
Reall•ed rKognl$ed galns and 1088e•
Realised galnslllosses) on fixed asset
Investments
182,982
{130,29 11
Nrt Inffle
169,854
18,988
Thls page does not fomi part of the ststutory finanual statements
Page 20